Intransal opioid
Phase 1Small molecule
Intransal opioid is one of 36 small molecule programs targeting Opioid Use Disorders. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
47 competitors in Opioid Use Disorder
#DrugCompanyPhaseTrials
1Suboxone
IIndivior Inc.
Approved
Sovaldi
GileadApproved
Dolophine
HHikma Pharmaceuticals LLC
Approved
Cabenuva
GSKApproved
Dilaudid
RRhodes Pharmaceuticals, L.P.
Approved
Oxycontin
PProtega
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Lucemyra
BBioCorRx Pharmaceuticals Inc
Approved
Narcan
SScienture
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intransal opioid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Kentucky